Osteopathic Procedure on Pain in Palliative Care (OSTEOPAL)

Centre Hospitalier Intercommunal Creteil

Status: Completed

Conditions: Pain

Treatments: Other: Questionnaire and treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT03939377

2018-A02655-50 (Other Identifier)

OSTEOPAL

Details and patient eligibility

About

The culture of the palliative is anchored more and more in France. In 2009, nearly 9 out of 10 French people (89%) believe that palliative care can reduce the suffering of people at the end of their lives. Despite the rise of palliative care in France, their access is not homogeneous between regions. In 2010, it is estimated that 2 French out of 3 likely to receive palliative care could not access it. Palliative care remains essential at the end of the patient's life, as well as for the family and caregivers.

The French government has put in place three national palliative care development programs: 2002-2005, 2008-2012, 2015-2018. The last program has unlocked a budget of 190 million euros for their development. It has been estimated from Social Security reimbursements, that the costs per patient over their last years of life are 26,000 euros, for a total of 13.5 million euros.

One of the most important aspects of palliative care is the comfort of the patients as well as their feelings in the care.

In order to best meet the expectations of cancer patients, some offer early palliative care that is effective in improving both the quality of life of the patient and its life expectancy.

Osteopathy is a manual alternative medicine whose goal is to restore the lack of mobility of tissues. It can be used as a complementary treatment when a specific support is put in place. The purpose of this study is to examine the effectiveness of osteopathy in the reduction of pain in adult patients in palliative care.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major patient (age> 18) male or female
• Patient hospitalized or admitted to a day hospital that can be followed
• EVA between 40/100 and 60/100
• Signed informed consent

Exclusion criteria

• Patients requiring a modification of analgesic molecule during the study.
• Clinical stability of the patient estimated during the duration of the study.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

80 participants in 2 patient groups, including a placebo group

Osteopathy

Experimental group

Description:

Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.

Treatment:

Other: Questionnaire and treatment

Simulate

Placebo Comparator group

Description:

The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.

Treatment:

Other: Questionnaire and treatment